Clinical Risk Management of Interactions Between Natural Products and Drugs

被引：13

作者：

De Smet, Peter A. G. M. ^{[1
]}

Floor-Schreudering, Annemieke ^{[2
]}

Bouvy, Marcel L. ^{[2
]}

Wensing, Michel ^{[3
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Clin Pharm, NL-6525 ED Nijmegen, Netherlands

[2] SIR Inst Pharm Practice & Policy, Leiden, Netherlands

[3] Radboud Univ Nijmegen, Med Ctr, IQ Healthcare, NL-6525 ED Nijmegen, Netherlands

来源：

CURRENT DRUG METABOLISM | 2008年 / 9卷 / 10期

关键词：

Herb-drug interactions; risk management;

D O I：

10.2174/138920008786927730

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 [生物化学与分子生物学]; 081704 [应用化学];

摘要：

Clinical risk management offers a systematic approach to minimize healthcare-related risks by paying attention to: (1) risk identification and assessment; (2) development and execution of risk reduction strategies; (3) evaluation of risk reduction strategies. This paper reviews these key areas for the risk of interactions between natural products and drugs (NPDIs) to explore how the impact of these interactions on public health can be minimized. It argues that specific components of clinical risk management need to be evaluated, before adoption, and then actively implemented if proven valuable.

引用

页码：1055 / 1062

页数：8

共 78 条

[1]

Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies [J].

Abarca, J ;

Colón, LR ;

Wang, VS ;

Malone, DC ;

Murphy, JE ;

Armstrong, EP .

JOURNAL OF MANAGED CARE PHARMACY, 2006, 12 (05) :383-389

[2]

Evaluation of consultation in community pharmacies with mystery shoppers [J].

Alte, Dietrich ;

Weitschies, Werner ;

Ritter, Christoph A. .

ANNALS OF PHARMACOTHERAPY, 2007, 41 (06) :1023-1030

[3]

[Anonymous], 2002, WHO Traditional Medicine Strategy 2002-2005. Eds

[4]

[Anonymous], 2008, Complementary and alternative medicine use among adults and children: United States

[5]

[Anonymous], 2008, PUBLIC ASSESSMENT RE

[6]

[Anonymous], 2006, BMC COMPLEM ALTERN M, DOI DOI 10.1186/1472-6882-6-15

[7]

Babb Dale A, 2007, Psychol Health Med, V12, P314, DOI 10.1080/13548500600621511

[8]

EFFECT OF PIPERINE ON BIOAVAILABILITY AND PHARMACOKINETICS OF PROPRANOLOL AND THEOPHYLLINE IN HEALTHY-VOLUNTEERS [J].

BANO, G ;

RAINA, RK ;

ZUTSHI, U ;

BEDI, KL ;

JOHRI, RK ;

SHARMA, SC .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (06) :615-617

[9]

Betancourt Joseph R, 2006, Consult Pharm, V21, P988, DOI 10.4140/TCP.n.2006.988

[10]

The development of quality circles/peer review groups as a method of quality improvement in Europe.: Results of a survey in 26 European countries [J].

Beyer, M ;

Gerlach, FM ;

Flies, U ;

Grol, R ;

Król, Z ;

Munck, A ;

Olesen, F ;

O'Riordan, M ;

Seuntjens, L ;

Szecsenyi, J .

FAMILY PRACTICE, 2003, 20 (04) :443-451

← 1 2 3 4 5 6 7 8 →